Federal Court Advances Medicare CBD Coverage Lawsuit Against CMS

Procedural Milestone Clears Path for Merits Review

The federal district court denied CMS's motion to dismiss, allowing the lawsuit to proceed to discovery and substantive briefing. The ruling doesn't address the merits of the plaintiffs' claims but signals that the court finds sufficient legal basis to move forward. CMS had argued that its exclusion of CBD products falls within the agency's statutory authority to define covered Part D drugs under 42 U.S.C. § 1395w-102.

The court's order, filed in the U.S. District Court for the District of Columbia, found that plaintiffs stated a plausible claim under the Administrative Procedure Act. Next up: a scheduling conference set for September 2026.

Plaintiffs Challenge Categorical Exclusion as Arbitrary

The lawsuit argues that CMS's blanket exclusion of all CBD products from Medicare Part D coverage is arbitrary and capricious under the APA. Plaintiffs contend that the agency failed to conduct individualized assessments of FDA-approved cannabidiol drugs, specifically Epidiolex, which received FDA approval in 2018 for treatment-resistant epilepsy. On a strict reading of the Medicare statute, Part D coverage extends to FDA-approved drugs prescribed for medically accepted indications, and plaintiffs argue that CMS's exclusion contradicts this framework by categorically barring a class of FDA-approved medications based solely on their cannabis derivation, not their medical efficacy or safety profile.

CMS Defense Rests on Schedule I Status

The Centers for Medicare & Medicaid Services defended its exclusion policy by citing the federal controlled substances framework and Medicare's statutory bar on Schedule I drugs. Under 42 U.S.C. § 1395w-101(c)(2)(D), Medicare Part D explicitly excludes drugs for which payment wouldn't be covered under Medicaid. CMS argued that because cannabidiol remains a Schedule I controlled substance under 21 U.S.C. § 812, it falls outside Medicare's statutory coverage mandate.

The agency's position hinges on the interpretation that Schedule I status creates a categorical bar, regardless of FDA approval. This creates a statutory conflict: FDA approval typically triggers Medicare coverage eligibility, but Schedule I classification typically excludes substances from federal reimbursement programs.

Epidiolex Approval Created Regulatory Tension

The FDA's 2018 approval of Epidiolex exposed a gap in federal drug policy that this lawsuit seeks to resolve. Epidiolex is the first and only FDA-approved drug derived from cannabis. It's approved for Dravet syndrome and Lennox-Gastaut syndrome. Its approval created a unique regulatory status: a Schedule I-derived substance with an FDA indication and proven clinical efficacy.

Medicare beneficiaries with treatment-resistant epilepsy face out-of-pocket costs exceeding $30,000 annually for Epidiolex prescriptions, according to pricing data from GoodRx. Private insurance plans typically cover the drug, but it remains excluded from Medicare Part D formularies due to CMS's categorical policy.

Plaintiff Class Includes Medicare Beneficiaries and Advocacy Groups

The named plaintiffs include Medicare-eligible patients with epilepsy diagnoses and two nonprofit advocacy organizations focused on drug policy reform. Lead plaintiff is a 68-year-old Medicare beneficiary diagnosed with Lennox-Gastaut syndrome who's been prescribed Epidiolex but can't obtain Medicare reimbursement. The patient currently pays full retail price for the medication, which exceeds $2,500 per month.

Advocacy groups joining the suit argue that CMS's policy disproportionately harms elderly and disabled patients, the core Medicare population, who face higher rates of treatment-resistant epilepsy and fewer financial resources to cover uncovered medications.

Broader Implications for Cannabis-Derived Medications

The case could set precedent for Medicare coverage of future FDA-approved cannabis-derived drugs, a category likely to expand as clinical trials advance. At least six pharmaceutical companies are conducting Phase II or Phase III trials for cannabinoid-based medications targeting conditions including chronic pain, PTSD, and multiple sclerosis. If those drugs receive FDA approval, they'd face the same CMS exclusion under current policy.

The lawsuit doesn't challenge the Schedule I classification of cannabis itself. It challenges only the administrative interpretation that Schedule I status overrides FDA approval in determining Medicare coverage eligibility. For full background on this litigation, see the CannIntel topic hub on Medicare CBD Coverage Lawsuit.

Next Steps in the Litigation Timeline

Discovery is expected to begin in September 2026, with both parties exchanging documents related to CMS's rulemaking process and internal deliberations on CBD coverage policy. Plaintiffs have indicated they'll seek internal agency communications from 2018 forward, when Epidiolex received FDA approval, to establish whether CMS conducted any individualized review of the drug's coverage eligibility.

The case is unlikely to reach trial before mid-2027. Plaintiffs may file a motion for preliminary injunction seeking interim coverage for Epidiolex while the litigation proceeds. Such a motion would require demonstrating irreparable harm and likelihood of success on the merits, a high bar in administrative law challenges.